Table 3.
Main metabolic criteria applied for the assessment of response to immunotherapy in skin cancer.
| Authors | Year | Criteria | CMR | PMR | PMD | SMD |
|---|---|---|---|---|---|---|
| Wahl et al. [47] | 2009 | PERCIST | Complete regression of all 18F-FDG-avid sites | SULpeak reduction in at least 30% in the target lesions | Increase in SULpeak of at least 30% or new lesions | None of the previously mentioned conditions |
| Sachpekidis et al. [48] | 2015 | EORTC | Complete regression of all 18F-FDG-avid sites | Minimum reduction of ±15–25% in SUV after the 1st cycle of chemotherapy, and >25% after more than one cycle | Increased SUVmax of ≥25% or appearance of new lesions | None of the previously mentioned conditions |
| Anwar et al. [49] | 2018 | PERCIMT | No new lesions (Clinical Benefit) |
No new lesions (Clinical Benefit) |
>4 new lesions with functional DM <1 cm, or three new lesions with functional diameter >1 cm or two new lesions with functional diameter >1.5 cm |
None of the previously mentioned conditions |
| Goldfarb et al. [50] Filippi et al. [51] |
2019 2022 |
iPERCIST | Complete regression of all 18F-FDG-avid sites | SULpeak reduction of at least 30% in the target lesions | Increase in SULpeak of at least 30% or new lesions (unconfirmed progressive disease/UPMD), needing confirmation (cPMD) with a further scan after 4–8 weeks. | None of the previously mentioned conditions |
| Ito et al. [52] | 2019 | Immunotherapy-modified PERCIST (imPERCIST5) |
Complete regression of all 18F-FDG-avid sites | Sum of SULpeak decreased by at least 30% | Increase in the sum of SULpeak by at least 30% | None of the previously mentioned conditions |